Abstract 3265: NKTR-255, a polymer-conjugated IL-15 enhances anti-tumor NK cell responses and synergizes with monoclonal antibodies to provide long-term survival in human lymphoma model
Takahiro Miyazaki(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Marlene Hennessy(Nektar Therapeutics (United States)), Laurie A. VanderVeen(Gilead Sciences (United States)), Murali K. Addepalli(Nektar Therapeutics (United States)), Peiwen Kuo(Nektar Therapeutics (United States)), Mekhala Maiti(Nektar Therapeutics (United States)), Joanna Wilczek(Nektar Therapeutics (United States)), Loui Madakamutil(Nektar Therapeutics (United States)), Neha Dixit(Nektar Therapeutics (United States)), Rhoneil Pena(Nektar Therapeutics (United States)), Wildaliz Nieves(Nektar Therapeutics (United States)), Sara Sheibani(Nektar Therapeutics (United States)), Saul Kivimäe(Nektar Therapeutics (United States))
Cited by 0
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403